Epidemiological Shifts and Prognostic Risk Factors for Early Postoperative Gram-Negative Bacterial Infections in Liver Transplant Recipients: A 10-Year Retrospective Study

When a liver fails, the only way to save a life is often to replace the organ entirely. This surgery, a monumental feat of modern medicine, offers a second chance to those with end-stage liver disease. However, the path to recovery is fraught with danger. Immediately after the operation, the patient's body is in a state of profound vulnerability. The massive physical trauma of the surgery, combined with the necessary medications that suppress the immune system to prevent organ rejection, leaves the patient open to infection. Among the many threats, bacteria that naturally live in the environment or within the human body can turn deadly. These are known as gram-negative bacteria, a large group of microbes that are particularly aggressive and difficult to treat when they cause infection in a weakened host. The situation becomes even more precarious when these bacteria evolve to resist the strongest antibiotics available, a phenomenon known as multidrug resistance. When a patient cannot be cured by standard drugs, the risk of losing the new organ or the patient's life rises sharply. Understanding exactly which bacteria are causing trouble, how they are changing over time, and which patients are most likely to suffer the worst outcomes is essential for doctors trying to keep transplant recipients alive.

In a ten-year study spanning from 2015 to 2024, researchers at Tongji Hospital in China examined the records of 1,115 patients who received a liver transplant from a donor who had died after cardiac arrest. They focused specifically on the first month after surgery, a critical window where infections are most likely to take hold. They identified 110 patients who developed an infection caused by gram-negative bacteria during this period. The team then dug deep into the medical data to understand the nature of these infections, the types of bacteria involved, and what factors predicted whether a patient would survive or die. Their goal was to map the landscape of these infections to help doctors make better decisions about treatment and care.

The researchers found that the threat of these infections was severe and often resistant to treatment. Of the 110 patients who got sick, nearly 70 percent were infected with bacteria that were multidrug-resistant, meaning the standard antibiotics used to kill them would not work. The most common culprits were two specific types of bacteria: Klebsiella pneumoniae and Acinetobacter baumannii. These germs were found most often in the abdominal cavity, where the surgery took place, and in the respiratory tract, where patients often rely on machines to help them breathe. When the team tested how well different antibiotics worked against these bacteria, the results were stark. The bacteria showed very high resistance to carbapenems, a class of powerful drugs often considered the last line of defense against serious infections. In fact, the bacteria were resistant to these drugs in nearly 88 percent of cases. However, the study did find a glimmer of hope in the data: a few older antibiotics, specifically minocycline and tigecycline, still showed the ability to kill a significant portion of these resistant bacteria, offering a potential tool for doctors when other options fail.

The study also looked at what made some patients more likely to get infected with these dangerous, drug-resistant strains. The researchers discovered that patients who had a very high score on a scale used to measure the severity of their liver disease before the surgery were much more likely to develop a multidrug-resistant infection. This score, known as the MELD score, reflects how sick a patient is; a higher number means a sicker patient. Those with a score of 30 or higher were significantly more likely to face a multidrug-resistant infection than those with lower scores. This suggests that the most critically ill patients, who often require longer stays in intensive care and more invasive procedures, are the ones most exposed to these tough bacteria.

Perhaps the most critical part of the research was identifying what led to death. Among the 110 patients who developed these infections, 16 died within 30 days. The researchers analyzed the medical history of these patients to find the warning signs. They found that four specific factors independently increased the risk of death. The most powerful predictor was the development of septic shock, a life-threatening condition where the body's response to infection causes blood pressure to drop dangerously low and organs to fail. Other major risk factors included kidney dysfunction, indicated by high levels of creatinine in the blood; a very low count of lymphocytes, a type of white blood cell essential for fighting infection; and the same high pre-surgery liver disease score that predicted the resistant infections. The data showed that patients who developed multidrug-resistant infections had a significantly lower chance of surviving the first month compared to those with infections that were easier to treat.

The researchers noted that the rate of these difficult-to-treat infections had actually decreased in the later years of their study, dropping from a higher rate in the 2015–2018 period to a lower rate in the 2019–2024 period. This improvement suggests that the hospital's efforts to control infections, manage antibiotic use, and refine their surgical and donor screening techniques were working. However, despite this progress, the bacteria that did cause infection remained stubbornly resistant to many common drugs. The study concludes that while the overall landscape is improving, the threat of these resistant bacteria remains a major hurdle. To protect patients, doctors must be vigilant, using local data to choose the right antibiotics immediately and focusing extra care on the sickest patients who are at the highest risk of developing septic shock or dying from these infections. The findings provide a clear roadmap for how to manage these complex cases, emphasizing that early intervention and tailored treatment are the keys to survival.